Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the... ανά L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group

Λήψη πλήρους κειμένου